Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 6, 2022; 10(28): 10180-10185
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10180
Chemotherapy, transarterial chemoembolization, and nephrectomy combined treated one giant renal cell carcinoma (T3aN1M1) associated with Xp11.2/TFE3: A case report
Peng Wang, Xiao Zhang, Shuo-Han Shao, Fa Wu, Fei-Zhou Du, Jun-Feng Zhang, Zhi-Way Zuo, Rui Jiang
Peng Wang, Xiao Zhang, Shuo-Han Shao, Fa Wu, Fei-Zhou Du, Jun-Feng Zhang, Zhi-Way Zuo, Rui Jiang, Department of Radiology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China
Author contributions: Wang P and Jiang R designed the research study; Zhang X, Shao SH, Wu F, and Du FZ performed the research; Zhang JF and Zuo ZW collected clinical data and radiation images; Wang P analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.
Supported by the Research and Development Program of The General Hospital of Western Theater Command, No. 2021-XZYG-C04 and 2021-XZYG-C05.
Informed consent statement: The patient provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rui Jiang, MM, Chief Doctor, Department of Radiology, The General Hospital of Western Theater Command, No. 270 Tianhui Road, Rongdu Avenue, Jinniu District, Chengdu 610083, Sichuan Province, China. jiangrui07@sina.com
Received: March 30, 2022
Peer-review started: March 30, 2022
First decision: June 16, 2022
Revised: July 14, 2022
Accepted: August 25, 2022
Article in press: August 25, 2022
Published online: October 6, 2022
Processing time: 181 Days and 1.3 Hours
Abstract
BACKGROUND

Renal cell carcinoma (RCC) with Xp11.2 translocation/TFE3 gene fusion is a rare and distinct subtype of RCC that is classified under tumors with translocation of the microphthalmia-associated transcriptional factor.

CASE SUMMARY

We report an adult case of Xp11.2 translocation advanced RCC with metastasis (T3aN1M1), after targeted treatment, alcohol ablation, and transarterial chemoembolization, who eventually underwent successful surgical excision. No recurrence or transfer was seen within one year, and the survival period was more than 3 years. A review of the relevant literature was conducted to improve our understanding of the pathogenesis, epidemiology, clinical manifestations, diagnosis, differential diagnosis, treatment, and other aspects of the disease.

CONCLUSION

Transarterial chemoembolization and ablation did not achieve the desired tumor reduction in this patient, but had a significant effect on reducing intraoperative bleeding and inhibiting tumor activity.

Keywords: Xp11.2/TFE3 Renal Cell Carcinoma; TACE; Axitinib; Zoledronic Acid; Targeted therapy; Multimodal imaging; Case report

Core Tip: Under the guidance of multimodality imaging, surgical resection, targeted chemotherapy, alcohol ablation, and transarterial chemoembolization were used to treat a case of Xp11.2/TFE3 (T3aN1M1) advanced renal cell carcinoma with good results. No recurrence or metastasis occurred within 1 year, with a partial response over 3 years. By reviewing this case and related literature, we can improve our understanding of the diagnosis, differential diagnosis and treatment of the disease.